Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Aura Biosciences Inc. (AURA) Insider Trading Activity
Healthcare • Biotechnology • 88 employees
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Total Value
-$549,435.34
Total Shares
476,304
Average Trade Value
-$39,245.38
Most Active Insider
De Los Pinos Elisabet
Total Activity: $377,965
Largest Single Transaction
$156,796
by De Los Pinos Elisabet on Feb 18, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
Senior Vice President, Finance
|
Feb 18, 2025 | 1,404 | $10,881 | 82,278 (-1.7%) | Sale | |
Chief Medical Officer
|
Feb 18, 2025 | 2,534 | $19,639 | 269,794 (-0.9%) | Sale | |
See Remarks
|
Feb 18, 2025 | 20,221 | $156,796 | 482,440 (-4.2%) | Sale | |
Chief Technology Officer
|
Feb 18, 2025 | 2,151 | $16,670 | 209,456 (-1.0%) | Sale | |
See Remarks
|
Feb 3, 2025 | 90,475 | $0 | 186,475 (+48.5%) | Grant | |
See Remarks
|
Feb 3, 2025 | 194,320 | $0 | 502,661 (+38.7%) | Grant | |
Chief Technology Officer
|
Feb 3, 2025 | 90,475 | $0 | 211,607 (+42.8%) | Grant | |
Chief Medical Officer
|
Feb 3, 2025 | 120,635 | $0 | 272,328 (+44.3%) | Grant | |
Senior Vice President, Finance
|
Feb 3, 2025 | 45,240 | $0 | 83,682 (+54.1%) | Grant | |
Vice President, Finance
|
Jan 21, 2025 | 1,001 | $7,679 | 38,442 (-2.6%) | Sale | |
See Remarks
|
Jan 21, 2025 | 15,955 | $122,381 | 304,692 (-5.2%) | Sale | |
Chief Medical Officer
|
Nov 18, 2024 | 11,822 | $110,663 | 151,693 (-7.8%) | Sale | |
Vice President, Finance
|
Oct 29, 2024 | 553 | $5,938 | 39,443 (-1.4%) | Sale | |
See Remarks
|
Oct 29, 2024 | 9,200 | $98,788 | 320,647 (-2.9%) | Sale |